Annexon, Inc. (ANNX)
| Market Cap | 868.37M +220.4% |
| Revenue (ttm) | n/a |
| Net Income | -198.33M |
| EPS | -1.19 |
| Shares Out | 163.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,918,335 |
| Open | 5.12 |
| Previous Close | 5.23 |
| Day's Range | 5.06 - 5.35 |
| 52-Week Range | 2.03 - 7.18 |
| Beta | 1.16 |
| Analysts | Buy |
| Price Target | 13.56 (+155.85%) |
| Earnings Date | Aug 13, 2026 |
About ANNX
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for ANNX stock is "Buy." The 12-month stock price target is $13.56, which is an increase of 155.85% from the latest price.
News
Annexon initiated with an Underperform at Citizens
Citizens initiated coverage of Annexon (ANNX) with an Underperform rating and $3 price target The company is developing first-in-class C1q inhibitors targeting the initiating step of the classical com...
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammat...
Annexon price target raised to $25 from $11 at Needham
Needham analyst Joseph Stringer raised the firm’s price target on Annexon (ANNX) to $25 from $11 and keeps a Buy rating on the shares. The company plans to announce topline…
Annexon to present vonaprument data at ASRS
Annexon (ANNX) announced an oral presentation on the neuroprotective effect of vonaprument at the American Society of Retina Specialists, or ASRS, 44th Annual Scientific Meeting being held July 15-18 ...
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
BRISBANE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammat...
Nedham biotech analysts hold an analyst/industry conference call
Analysts discuss Annexon (ANNX) Vonaprument in geographic atrophy on an Analyst/Industry conference call on July 9 at 9 am.
Annexon Transcript: AGM 2026
The meeting covered progress on late-stage therapies for neuroinflammatory diseases, approved all four shareholder proposals, and confirmed a strong cash position through 2027. Key milestones include regulatory submissions and pivotal data readouts.
Annexon Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Pivotal phase III data for vonaprument in geographic atrophy is expected in Q4 2026, focusing on vision preservation as a key differentiator. The company is also advancing tanruprubart for Guillain-Barré syndrome and ANX1502, with a strong cash position supporting execution of major milestones.
Annexon Transcript: Jefferies Global Healthcare Conference 2026
Upcoming catalysts include late-stage data for GBS, GA, and ANX1502, with all programs showing strong differentiation and commercial potential. GA phase III aims to confirm vision preservation, while GBS targets a large, underserved market. Key data readouts are expected in 2024.
Annexon to Participate in Upcoming June Investor Conferences
BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammato...
Annexon Transcript: Bank of America Global Healthcare Conference 2026
The company highlighted differentiated complement pathway therapies for neuroinflammatory diseases, with late-stage programs in geographic atrophy and Guillain-Barré syndrome showing strong efficacy and safety. Commercial and regulatory strategies are advancing in both the U.S. and Europe, with additional pipeline progress in small molecule candidates.
Annexon initiated with a Neutral at Goldman Sachs
Goldman Sachs initiated coverage of Annexon (ANNX) with a Neutral rating and $7 price target Annexon is a clinical-stage biotechnology company developing therapeutics for neuroinflammatory diseases vi...
110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS
CONSHOHOCKEN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- May is GBS|CIDP Awareness Month and this year marks 110 years since the discovery of Guillain-Barré syndrome (GBS), which was first identified and n...
Annexon reports Q1 EPS (23c), consensus (30c)
“As we execute toward major milestones in 2026, we are sharply focused on our strategic priorities across the organization,” said Douglas Love, president and chief executive officer of Annexon (ANNX).
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA
Annexon Quarterly report: Q1 2026
Annexon has published its Q1 2026 quarterly earnings report on May 7, 2026.
Annexon Earnings release: Q1 2026
Annexon released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Annexon to Present at the Bank of America Securities Health Care Conference 2026
BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammato...
Annexon Proxy statement: Proxy filing
Annexon filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Annexon Proxy statement: Proxy filing
Annexon filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Annexon Slides: Corporate presentation
Annexon has posted slides in relation to its latest quarterly earnings report, which was published on April 27, 2026.
Annexon Proxy statement: Proxy filing
Annexon filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Annexon Transcript: 25th Annual Needham Virtual Healthcare Conference
2026 is set to be a milestone year, with anticipated regulatory filings and pivotal data readouts for late-stage programs in GBS, GA, and ANX1502. Vonaprument’s differentiated C1q-targeting approach in GA is advancing through a robust phase III trial, while GBS and ANX1502 programs are progressing toward key regulatory and clinical milestones.
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference
BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflamma...
Chardan sees positive read-through to Annexon’s vonaprument from Apellis deal
Biogen (BIIB) has agreed to acquire Apellis Pharmaceuticals (APLS) for $41 per share, bringing complement inhibitors Syfovre and Empaveli into its portfolio, with Syfovre’s $589M in 2025 sales viewed ...